Yesterday, Amarin (AMRN) revised its 2019 revenue guidance upwards from $350 million to $380 million–$420 million due to higher-than-anticipated demand for Vascepa in the first half of 2019.
On March 28, Amarin (AMRN) issued a press release announcing the submission of an sNDA (supplemental new drug application) to the FDA seeking label expansion for Vascepa.
In its first-quarter earnings conference call, Amarin (AMRN) reiterated its fiscal 2019 net revenue guidance of $350 million, which represents a YoY rise of more than 50%.
Sangamo is conducting Phase 1/2 studies on SB-318 and SB-913 for treating MPS (mucopolysaccharidosis) I and MPS II inherited metabolic disorders, respectively.
On April 5, Sangamo Therapeutics (SGMO) closed at $12.58, 3.62% above its previous closing price, 100.96% above its 52-week low of $6.26, and 38.78% below its 52-week high of $20.55.
Wall Street analysts have projected Sarepta Therapeutics’ revenues to be $395.55 million, $611.37 million, and $1101.00 million, for fiscal 2019, fiscal 2020, and fiscal 2021, respectively.
On February 27, Amarin (AMRN) closed at $21.18, 5.85% higher than its previous closing price, 801.28% higher than its 52-week low of $2.35, and 9.24% below its 52-week high of $23.33.
In its investor presentation, Amarin (AMRN) highlighted the annual death toll attributable to cardiovascular disease in the United States to more than 800,000 while the yearly treatment cost is estimated at $555 billion.
With its 2018 unaudited results, as announced in an investor presentation, Amarin (AMRN) has guided for net total revenue in the range of $72 million–$76 million…
Amarin (AMRN) expects Vascepa to witness robust demand trends in fiscal 2019 driven by demonstrated efficacy of the drug coupled with the company’s increasing focus on creating awareness.
In a press release issued on January 4, Amarin (AMRN) has announced that it will be submitting a supplemental new drug application (or sNDA) to the FDA in fiscal 2019.
